Abstract: A method of reducing an aromatic ring or a cyclic, allylic ether in a compound includes preparing a reaction mixture including a compound including an aromatic moiety or a cyclic, allylic ether moiety, an alkali metal, and either ethylenediamine, diethylenetriamine, triethylenetetramine, or a combination thereof, in an ether solvent; and reacting the reaction mixture at from ?20° C. to 30° C. for a time sufficient to reduce a double bond in the aromatic moiety to a single bond or to reduce the cyclic, allylic ether moiety.

Abstract: A method of reducing an aromatic ring or a cyclic, allylic ether in a compound includes preparing a reaction mixture including a compound including an aromatic moiety or a cyclic, allylic ether moiety, an alkali metal, and either ethylenediamine, diethylenetriamine, triethylenetetramine, or a combination thereof, in an ether solvent; and reacting the reaction mixture at from ?20° C. to 30° C. for a time sufficient to reduce a double bond in the aromatic moiety to a single bond or to reduce the cyclic, allylic ether moiety.

Abstract: Methods of detecting platinum and copper in a test sample are provided. Kits for use in detecting platinum and copper in a test sample also are provided.

Abstract: Methods of detecting platinum and copper in a test sample are provided. Kits for use in detecting platinum and copper in a test sample also are provided.

Abstract: Methods of detecting platinum and copper in a test sample are provided. Kits for use in detecting platinum and copper in a test sample also are provided.

Abstract: Provided herein is a fluorogenic probe that selectively undergoes a [2,3]-sigmatropic rearrangement (seleno-Mislow-Evans rearrangement) with H2O2, followed by an acetal hydrolysis, to produce a green fluorescent molecule in seconds. Also provided herein is a method of identifying or visualizing the presence of H2O2 in a cell, tissue, organ, or organism that includes contacting the cell, tissue, organ, or organism with the fluorogenic probe. Also provided herein is a method of identifying or quantifying the presence of H2O2 in a sample that includes adding to or mixing in the sample the fluorogenic probe.

Abstract: A method of reducing an aromatic ring or a cyclic, allylic ether in a compound includes preparing a reaction mixture including a compound including an aromatic moiety or a cyclic, allylic ether moiety, an alkali metal, and either ethylenediamine, diethylenetriamine, triethylenetetramine, or a combination thereof, in an ether solvent; and reacting the reaction mixture at from ?20° C. to 30° C. for a time sufficient to reduce a double bond in the aromatic moiety to a single bond or to reduce the cyclic, allylic ether moiety.

Abstract: Provided herein are analytical methods utilizing a self-limiting catalytic reaction, and compositions and kits useful therefore. In one aspect the method is used to quantify Pd, and in another, the method is a horseradish peroxidase assay.

Abstract: This document relates to methods and materials for increasing viral vector infectivity. For example, methods and materials for using spliceosome inhibitors (e.g., U2 snRNP spliceosome inhibitors such as meayamycin B or pladienolide derivative E7107) to increase viral vector (e.g., adeno-associated virus-based vector) infectivity are provided.

Abstract: Provided herein are compounds useful in treating exposure to an organophosphorus compound, such as a nerve agent, pesticide, or, generally, an acetylcholinesterase inhibitor, such as sarin. Compositions, e.g. pharmaceutical compositions or dosage forms, comprising the compounds also are provided herein. Methods of treating a patient exposed to a nerve agent, pesticide, or, generally, an acetylcholinesterase inhibitor, e.g., an organophosphorus compound, such as sarin, also are provided.

Abstract: Methods of detecting platinum and copper in a test sample are provided. Kits for use in detecting platinum and copper in a test sample also are provided.

Abstract: Provided herein are analytical methods utilizing a self-limiting catalytic reaction, and compositions and kits useful therefore. In one aspect the method is used to quantify Pd, and in another, the method is a horseradish peroxidase assay.

Abstract: The present invention provides novel analogs of FR901464, as well as an improved methodology for preparing FR901464 and its analogs. These compounds display an anti-cancer activity and are candidates for therapies against a number of disease states associated with dysfunctional RNA splicing.

Abstract: This document relates to methods and materials for increasing viral vector infectivity. For example, methods and materials for using spliceosome inhibitors (e.g., U2 snRNP spliceosome inhibitors such as meayamycin B or pladienolide derivative E7107) to increase viral vector (e.g., adeno-associated virus-based vector) infectivity are provided.

Abstract: The present invention provides novel analogs of FR901464, as well as an improved methodology for preparing FR901464 and its analogs. These compounds display an anti-cancer activity and are candidates for therapies against a number of disease states associated with dysfunctional RNA splicing.

Abstract: A selective, fluorescent “turn-on” probe and method for the detection of ozone in biological and atmospheric samples, wherein the method of detecting ozone in a sample comprises the steps of (1) contacting the sample with a fluorophore capable of undergoing allylic ether or allylic ester cleavage and (2) detecting fluorescence in the sample.

Abstract: The present invention provides novel analogs of FR901464, as well as an improved methodology for preparing FR901464 and its analogs. These compounds display an anti-cancer activity and are candidates for therapies against a number of disease states associated with dysfunctional RNA splicing.

Abstract: The present invention is a method to produce and to use a fluorogenic chemodosimeter for the detection of mercury ions in a sample at temperature ranges from about 0° C. to 100° C.

Abstract: Hydroxymethyl fluorescein derivatives are provided. The derivatives can be easily conjugated to other molecules, and are more permeable than other fluorescein derivatives. Methods of making the derivatives are also provided.

Abstract: The present invention provides novel analogs of FR901464, as well as an improved methodology for preparing FR901464 and its analogs. These compounds display an anti-cancer activity and are candidates for therapies against a number of disease states associated with dysfunctional RNA splicing.